N-terminal peptide of type III procollagen - A possible predictor of colorectal carcinoma recurrence

被引:0
作者
Plebani, M
Basso, D
Roveroni, G
DePaoli, M
Galeotti, F
Corsini, A
机构
[1] AZIENDA OSPED, DIV CHIRURG 2, I-35128 PADUA, ITALY
[2] CTR BIOMED RES, COSTELFRANCO VENETO, ITALY
关键词
colorectal carcinoma; laminin; C-terminal peptide of Type I procollagen (PIP); N-terminal peptide of Type III procollagen (PIIIP); carcinoembryonic antigen; CA; 19-9; tissue plasminogen activator;
D O I
10.1002/(SICI)1097-0142(19970401)79:7<1299::AID-CNCR5>3.0.CO;2-C
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND. The first step of colorectal carcinoma spread depends on the ability of the tumor cells to degrade and invade the extracellular matrix (ECM). The objectives of the current study were to evaluate the serum pattern of laminin, C-terminal peptide of Type I (PIP), and N-terminal peptide of Type III (PIIIP) procollagens, markers of ECM synthesis, in the follow-up of patients after resection for colorectal carcinoma and to evaluate their role in predicting local recurrence or metastases. METHODS. A total of 32 patients who had undergone resection for colorectal carcinoma were followed for a median period of 24 months (range, 6-36 months). Every 3 months, laminin, PIP, and PIIIP were measured in the sera together with the tumor markers carcinoembryonic antigen (CEA), CA 19-9, and tissue plasminogen activator (TPA). Twenty-one patients (Group 1) had no signs of recurrence, whereas the remaining 11 (Group 2) developed hepatic (n = 7) or pulmonary (n = 4) metastases. RESULTS. No variations were observed in either group for laminin, CEA, CA 19-9, or TPA, whereas significant increases in PIP and PIIIP were observed in both groups 3 months after surgery. The increase in PIP and PIIIP at the S-month follow-up was significantly greater in Group 1 than in Group 2. The difference between values at 3 months and basal values enabled a discrimination between Group 1 and Group 2, with a sensitivity of 36% and 91% and a specificity of 71% and 71% for PIP and PIIIP, respectively. CONCLUSIONS. The authors believe PIIIP is useful as an early prognostic indicator of recurrence in the follow-up of patients who have undergone radical resection for colorectal carcinoma. (C) 1997 American Cancer Society.
引用
收藏
页码:1299 / 1303
页数:5
相关论文
共 35 条
[1]   ROLE OF CEA, TPA, AND CA 19-9 IN THE EARLY DETECTION OF LOCALIZED AND DIFFUSE RECURRENT RECTAL-CANCER [J].
BARILLARI, P ;
BOLOGNESE, A ;
CHIRLETTI, P ;
CARDI, M ;
SAMMARTINO, P ;
STIPA, V .
DISEASES OF THE COLON & RECTUM, 1992, 35 (05) :471-476
[2]   FOLLOW-UP OF PATIENTS WITH COLORECTAL-CANCER - A METAANALYSIS [J].
BRUINVELS, DJ ;
STIGGELBOUT, AM ;
KIEVIT, J ;
VANHOUWELINGEN, HC ;
HABBEMA, JDF ;
VANDEVELDE, CJH .
ANNALS OF SURGERY, 1994, 219 (02) :174-182
[3]   PROCOLLAGEN-III PEPTIDE CONCENTRATIONS IN SERUM OF PATIENTS WITH CHRONIC ACTIVE HEPATITIS COMPARED WITH MILD HEPATIC DISORDERS [J].
COLLAZOS, J ;
DIAZ, F .
CLINICAL BIOCHEMISTRY, 1994, 27 (03) :189-191
[4]  
CRISSMAN JD, 1988, CANCER RES, V48, P4065
[5]   USE OF CA-19-9 IN THE EARLY DETECTION OF RECURRENCES IN COLORECTAL-CANCER - COMPARISON WITH CEA [J].
FILELLA, X ;
MOLINA, R ;
PIQUE, JM ;
GARCIAVALDECASAS, JC ;
GRAU, JJ ;
NOVELL, F ;
ASTUDILLO, E ;
DELACY, A ;
DANIELS, M ;
BALLESTA, AM .
TUMOR BIOLOGY, 1994, 15 (01) :1-6
[6]   THE N-TERMINAL PROPEPTIDE OF COLLAGEN TYPE-III IN SERUM REFLECTS ACTIVITY AND DEGREE OF FIBROSIS IN PATIENTS WITH CHRONIC LIVER-DISEASE [J].
FREI, A ;
ZIMMERMANN, A ;
WEIGAND, K .
HEPATOLOGY, 1984, 4 (05) :830-834
[7]   SERUM MARKERS OF HEPATIC FIBROGENESIS IN CHRONIC HEPATITIS TYPE-C TREATED WITH ALFA-2A INTERFERON [J].
GALLORINI, A ;
PLEBANI, M ;
PONTISSO, P ;
CHEMELLO, L ;
MASIERO, M ;
MANTOVANI, G ;
ALBERTI, A .
LIVER, 1994, 14 (05) :257-264
[8]   ROLLING AND ADHESION OF HUMAN TUMOR-CELLS ON VASCULAR ENDOTHELIUM UNDER PHYSIOLOGICAL FLOW CONDITIONS [J].
GIAVAZZI, R ;
FOPPOLO, M ;
DOSSI, R ;
REMUZZI, A .
JOURNAL OF CLINICAL INVESTIGATION, 1993, 92 (06) :3038-3044
[9]   Serum procollagen type III peptide in chronic hepatitis B - Relationship to disease activity and response to interferon-alpha therapy [J].
Giustina, G ;
Fattovich, G ;
DePaoli, M ;
Guido, M ;
Favarato, S ;
Rugge, M ;
Alberti, A ;
Ruol, A ;
Plebani, M .
INTERNATIONAL JOURNAL OF CLINICAL & LABORATORY RESEARCH, 1996, 26 (01) :33-36
[10]  
GRESSNER AM, 1991, EUR J CLIN CHEM CLIN, V29, P293